Register entry
- Registered sites
- 0
- Active NDC listings
- 3
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
33 active NDC listings: 3 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 3.
| Dosage form | NDCs |
|---|---|
| granule | 1 |
| solution | 1 |
| tablet, film coated | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| pel healthcare llc | 3 |
Catalogue
Marketed products
3| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | CANTHARIDIN TOPICAL SOUTION | solution | 80426-046DRUG FOR FURTHER PROCESSING |
| - | Montelukast sodium | granule | 80426-041DRUG FOR FURTHER PROCESSING |
| - | Risedronate Sodium | tablet, film coated | 80426-042DRUG FOR FURTHER PROCESSING |
Enquiry
Common questions
- Is PEL HEALTHCARE LLC FDA approved?
- PEL HEALTHCARE LLC holds no registered establishment of its own; 3 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does PEL HEALTHCARE LLC make?
- 3 products are listed under PEL HEALTHCARE LLC in the openFDA NDC Directory, most often as granule; solution; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.